|
|
|
|
|
|
|
|
 
|
Pancreas Cancer
News and Archives |
|
 |
For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer | |
| June 15, 2002 | Efficacy of Ukrain in the Treatment of Pancreatic Cancer | |
| June 15, 2002 | Endosonography-Guided Fine Needle Aspiration Biopsy in the Evaluation of Pancreatic Masses | |
| June 15, 2002 | Intraoperative Hyperthermia and Chemoradiotherapy for Inoperable Pancreatic Carcinoma | |
| June 6, 2002 | MGI PHARMA Initiates Drug Combination Trial of Irofulven With Xeloda in Patients With Advanced Solid Tumors - Phase 1 Dose-Escalating Trial to Evaluate Novel Combination Therapy | |
| June 4, 2002 | Lorus Receives Fast Track Designation from FDA for Virulizin(R) for the Treatment of Pancreatic Cancer | |
| June 1, 2002 | Successful Treatment of a T1 Cancer of the Pancreatic Head with High Dose Rate Brachytherapy and External Radiotherapy | |
| June 1, 2002 | Gemcitabine-Radiotherapy in Patients with Locally Advanced Pancreatic Cancer | |
| June 1, 2002 | Inflammation and the Development of Pancreatic Cancer | |
| June 1, 2002 | Aberrant p16(INK4A) and DPC4/Smad4 Expression in Intraductal Papillary Mucinous Tumours of the Pancreas is Associated with Invasive Ductal Adenocarcinoma | |
| May 29, 2002 | Cell Genesys Initiates Phase II Trial of GVAX(R) Cancer Vaccine in Patients With Inoperable Pancreatic Cancer | |
| May 21, 2002 | New Bay 43-9006 Phase I Data Presented at 2002 ASCO Meeting | |
| May 21, 2002 | AVI BioPharma to Present AVICINE Pancreatic Cancer Survival Data At American Society of Clinical Oncology | |
| May 20, 2002 | A Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy in Patients with Locally Advanced Pancreatic Cancer | |
| May 20, 2002 | Johnson & Johnson Pharmaceutical Research and Development Announces Results from Phase III Trials for R115777 | |
| May 20, 2002 | Treatment of Common Bile Duct Obstruction by Pancreatic Cancer Using Various Stents: Single-Center Experience | |
| May 20, 2002 | High Expression of Tumor-associated Antigen RCAS1 in Pancreatic Ductal Adenocarcinoma is an Unfavorable Prognostic Marker | |
| May 18, 2002 | Combination Therapy With Gemzar and Alimta Shows Activity In Treatment of Advanced Pancreatic Cancer | |
| May 16, 2002 | 38th Annual Meeting of the American Society of Clinical Oncology Features More Than 200 Abstracts On Taxotere(R) | |
| May 16, 2002 | Fujirebio Diagnostics CA19-9 RIA Test for Pancreatic Cancer Receives FDA Clearance for US Marketing | |
| May 15, 2002 | MUC4 Expression Increases Progressively in Pancreatic Intraepithelial Neoplasia | |
| May 15, 2002 | Irinotecan and Gemcitabine in Patients with Solid Tumors: Phase I Trial | |
| May 15, 2002 | Pancreatic Cancer After Remote Peptic Ulcer Surgery | |
| May 15, 2002 | Implications of Peritoneal Washing Cytology in Patients with Potentially Resectable Pancreatic Cancer | |
| May 14, 2002 | Genentech and OSI Pharmaceuticals Announce FDA Fast-track Designation for Tarceva | |
| May 2, 2002 |
Rabbit
Liver Protein Provides Clues to Improving Cancer Therapy Study From St. Jude Children's Research Hospital Shows Protein Activates Anti-Cancer Drug CPT-11 |
|
| May 2, 2002 | OSI Pharmaceuticals Announces Completion Of Initial Cohort In Phase III Pancreatic Cancer Trial For Tarceva | |
| May 1, 2002 | Current and Future Strategies for Combined-Modality Therapy in Pancreatic Cancer | |
| May 1, 2002 | AVI BioPharma Announces Plans to Initiate Phase III Clinical Trial In Pancreatic Cancer With AVICINE | |
| May 1, 2002 | Tumor Response and Clinical Benefit in Neuroendocrine Tumors After 7.4 GBq (90)Y-DOTATOC | |
| May 1, 2002 | Concurrent Chemoradiotherapy with Gemcitabine and Cisplatin for Pancreatic Cancer: From the Laboratory to the Clinic | |
| May 1, 2002 | Length and Quality of Survival after External-beam Radiotherapy with Concurrent Continuous 5-fluorouracil Infusion for Locally Unresectable Pancreatic Cancer | |
| May 1, 2002 | A Prospective Pancreatographic Study of the Prevalence of Pancreatic Carcinoma in Patients with Diabetes Mellitus | |
| May 1, 2002 | Current and Future Strategies for Combined-Modality Therapy in Pancreatic Cancer | |
| April 17, 2002 |
MGI
PHARMA Stops Phase 3 Irofulven Clinical Trial for Refractory
Pancreatic Cancer Patients Irofulven Development Program Continues For Other Tumor Targets |
|
| April 15, 2002 | Low-Dose Trimetrexate Glucuronate and Protracted 5-Fluorouracil Infusion in Previously Untreated Patients with Advanced Pancreatic Cancer | |
| April 15, 2002 | Gemcitabine and Oxaliplatin for Patients with Advanced or Metastatic Pancreatic Cancer: a North Central Cancer Treatment Group (NCCTG) Phase I Study | |
| April 15, 2002 | Pancreatic Resection for Locally Advanced Primary and Metastatic Nonpancreatic Neoplasms | |
| April 15, 2002 | A Prospective Cohort Study of Cigarette Smoking and Pancreatic Cancer in Japan | |
| April 15, 2002 | Indium-111-Pentetreotide Prolongs Survival in Gastroenteropancreatic Malignancies | |
| April 15, 2002 | Preoperative Chemoradiation in the Management of Adenocarcinoma of the Body of the Pancreas | |
| April 10, 2002 | Isis Pharmaceuticals Reports Preliminary Phase II Data On ISIS 2503 Plus Chemotherapy in Pancreatic Cancer | |
| April 9, 2002 | BAY 43-9006 Data Presented at 2002 AACR Meeting | |
| April 8, 2002 | Millennium Researchers Announce Preclinical Findings of its Proteasome Inhibitor MLN341 Against Several Solid Tumor Types | |
| April 8, 2002 | Lorus presents new data from its immunotherapeutic program at American Association for Cancer Research conference | |
| April 8, 2002 | GlycoGenesys and Elan Complete Phase IIa Pancreatic Cancer Study | |
| April 5, 2002 | FDA Grants Approval to Market SecreFlo(TM) for Pancreatic Assessment | |
| April 3, 2002 | Independent Review of Phase II Study Confirms SuperGen's Orathecin(TM) Is Active in Pancreatic Cancer Patients Who Failed Prior Treatments | |
| April 1, 2002 | Is the Therapeutic Index Better with Gemcitabine-based Chemoradiation than with 5-fluorouracil-based Chemoradiation in Locally Advanced Pancreatic Cancer? | |
| April 1, 2002 | En Bloc Resection for Locally Advanced Cancer of the Pancreas. Is it Worthwhile? | |
| April 1, 2002 | Human Heparanase-1 Gene Expression in Pancreatic Adenocarcinoma | |
| April 1, 2002 | Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer | |
| April 1, 2002 | Cryoablation of Unresectable Pancreatic Cancer | |
| April 1, 2002 | Parathyroid Hormone-related Protein as a Novel Tumor Marker in Pancreatic Adenocarcinoma | |
| April 1, 2002 | Human Macrophage Metalloelastase Worsens the Prognosis of Pancreatic Cancer | |
| April 1, 2002 | Dual-Phase Helical CT of Pancreatic Adenocarcinoma: Assessment of Resectability Before Surgery | |
| April 1, 2002 | Photodynamic Therapy for Cancer of the Pancreas | |
|
[Abstract]
Endosonography-Guided
Fine Needle Aspiration Biopsy in the Evaluation of Pancreatic
Masses [Abstract]
Intraoperative
Hyperthermia and Chemoradiotherapy for Inoperable Pancreatic
Carcinoma [Abstract]
MGI
PHARMA Initiates Drug Combination Trial of Irofulven With Xeloda
in Patients With Advanced Solid Tumors - Phase 1 Dose-Escalating
Trial to Evaluate Novel Combination Therapy MGI PHARMA, Inc., today announced that it has initiated a Phase 1 clinical trial of irofulven, its novel anti-cancer compound, in combination with the anti-tumor drug Xeloda® (capecitabine) in patients with advanced solid tumors. ...full article
Lorus
Receives Fast Track Designation from FDA for Virulizin(R) for
the Treatment of Pancreatic Cancer Lorus Therapeutics Inc. ("Lorus") announced today that the U.S. Food and Drug Administration ("FDA") has granted Fast Track Designation for Virulizin® in the treatment of pancreatic cancer. Virulizin® is the company's most advanced drug in clinical development, currently being studied in a North American Phase III clinical trial. ...full article
Successful
Treatment of a T1 Cancer of the Pancreatic Head with High Dose
Rate Brachytherapy and External Radiotherapy [Abstract]
Gemcitabine-Radiotherapy
in Patients with Locally Advanced Pancreatic Cancer [Abstract]
Inflammation
and the Development of Pancreatic Cancer [Abstract]
Aberrant
p16(INK4A) and DPC4/Smad4 Expression in Intraductal Papillary
Mucinous Tumours of the Pancreas is Associated with Invasive
Ductal Adenocarcinoma [Abstract]
Cell
Genesys Initiates Phase II Trial of GVAX(R) Cancer Vaccine in
Patients With Inoperable Pancreatic Cancer Cell Genesys, Inc. today announced the initiation of a Phase II clinical trial of GVAX® pancreatic cancer vaccine in patients with inoperable or metastatic pancreatic cancer. This trial was prompted by compelling results from an initial Phase I clinical trial of GVAX® pancreatic cancer vaccine which demonstrated prolonged, disease-free survival in three of eight patients treated at the higher dose levels. ...full article
New
Bay 43-9006 Phase I Data Presented at 2002 ASCO Meeting Bayer Corporation and Onyx Pharmaceuticals, Inc. announced today preliminary Phase I data from clinical trials for a novel anticancer agent. BAY 43-9006, an orally active small molecule Raf kinase inhibitor, was discovered and is being co-developed in a collaboration between Onyx and Bayer. ...full article
AVI
BioPharma to Present AVICINE Pancreatic Cancer Survival Data
At American Society of Clinical Oncology AVI BioPharma, Inc. will present complete survival data from a Phase II trial of the company's AVICINE® cancer vaccine today at the American Society of Clinical Oncology (ASCO). ...full article
A
Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy
in Patients with Locally Advanced Pancreatic Cancer [Abstract]
Johnson
& Johnson Pharmaceutical Research and Development Announces
Results from Phase III Trials for R115777 Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (PRD) today announced results of two Phase III clinical trials of R115777 in gastrointestinal cancers. These results were presented at the American Society of Clinical Oncology (ASCO) annual meeting. ...full article
Treatment
of Common Bile Duct Obstruction by Pancreatic Cancer Using Various
Stents: Single-Center Experience [Abstract]
High
Expression of Tumor-associated Antigen RCAS1 in Pancreatic Ductal
Adenocarcinoma is an Unfavorable Prognostic Marker [Abstract]
Combination
Therapy With Gemzar and Alimta Shows Activity In Treatment of
Advanced Pancreatic Cancer New, preliminary research findings suggest that a combination of Gemzar® (gemcitabine HCl) and Alimta® (pemetrexed) is active in the treatment of pancreatic cancer, the fourth leading cause of cancer death in the United States. ...full article
38th
Annual Meeting of the American Society of Clinical Oncology Features
More Than 200 Abstracts On Taxotere(R) The results of Phase III clinical studies involving the use of the chemotherapy agent Taxotere® (docetaxel) for Injection Concentrate to treat patients with early stage breast cancer, ovarian cancer and non-small cell lung cancer (NSCLC) will be presented this week at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. The ASCO meeting begins on Saturday, May 18th and runs through Tuesday, May 21st. ...full article
Fujirebio
Diagnostics CA19-9 RIA Test for Pancreatic Cancer Receives FDA
Clearance for US Marketing Polymedco, Inc. is pleased to announce the FDA marketing clearance for the Fujirebio Diagnostics, Inc. CA19-9(TM) Radioimmunoassay for monitoring of disease status in pancreatic cancer patients. Fujirebio Diagnostics, Inc. (FDI), a leading oncology diagnostics company, has partnered with Polymedco, Inc. to provide the highest standard of diagnostic tools and services to the oncology medical community. ...full article
[Abstract]
MUC4 Expression
Increases Progressively in Pancreatic Intraepithelial Neoplasia [Abstract]
Pancreatic
Cancer After Remote Peptic Ulcer Surgery [Abstract]
Implications
of Peritoneal Washing Cytology in Patients with Potentially Resectable
Pancreatic Cancer [Abstract]
Genentech
and OSI Pharmaceuticals Announce FDA Fast-track Designation for
Tarceva Genentech, Inc. and OSI Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated Tarceva(TM) (erlotinib HCl, OSI-774) a Fast Track Product for the treatment of chemotherapy-naive Stage III/IV non-small cell lung cancer patients. Tarceva(TM) is a small molecule EGFR inhibitor being developed by Genentech, OSI and Roche. ...full article
Rabbit
Liver Protein Provides Clues to Improving Cancer Therapy A rabbit liver protein can effectively activate the promising anti-cancer drug CPT-11, according to scientists at St. Jude Children's Research Hospital. This discovery could lead to more effective treatment for patients using CPT-11, improving therapy of solid-tumor cancers in adults and children. ...full article
OSI
Pharmaceuticals Announces Completion Of Initial Cohort In Phase
III Pancreatic Cancer Trial For Tarceva OSI Pharmaceuticals announced today that it has completed the initial stage of the on-going Phase III trial for Tarceva(TM) (erlotinib HCl, OSI-774), in pancreatic cancer. The Phase III study is being conducted by OSI in collaboration with the National Cancer Institute of Canada Clinical Trials Group and is an 800 patient randomized, controlled study assessing the use of Tarceva(TM) in combination with gemcitabine (Gemzar®), the only approved front-line chemotherapy treatment for pancreatic cancer. Improvement in patient survival is the primary end-point in this study. ...full article
AVI
BioPharma Announces Plans to Initiate Phase III Clinical Trial
In Pancreatic Cancer With AVICINE AVI BioPharma, Inc. today announced that the company plans to initiate a Phase III clinical trial program in pancreatic cancer with its therapeutic cancer vaccine, AVICINE®. ...full article
Tumor
Response and Clinical Benefit in Neuroendocrine Tumors After
7.4 GBq (90)Y-DOTATOC [Abstract]
Concurrent
Chemoradiotherapy with Gemcitabine and Cisplatin for Pancreatic
Cancer: From the Laboratory to the Clinic [Abstract]
Length
and Quality of Survival after External-beam Radiotherapy with
Concurrent Continuous 5-fluorouracil Infusion for Locally Unresectable
Pancreatic Cancer [Abstract]
A
Prospective Pancreatographic Study of the Prevalence of Pancreatic
Carcinoma in Patients with Diabetes Mellitus [Abstract]
Prospective
Study of Diet and Pancreatic Cancer in Male Smokers [Abstract]
Matrix
Metalloproteinase-2 in Pancreatic Juice for Diagnosis of Pancreatic
Cancer [Abstract]
Current
and Future Strategies for Combined-Modality Therapy in Pancreatic
Cancer [Abstract]
Current
and Future Strategies for Combined-Modality Therapy in Pancreatic
Cancer [Abstract]
MGI
PHARMA Stops Phase 3 Irofulven Clinical Trial for Refractory
Pancreatic Cancer Patients MGI PHARMA, INC., today announced that it has stopped its Phase 3 clinical trial of its anti-cancer drug candidate, irofulven, for gemcitabine-refractory pancreatic cancer patients. ...full article
Low-Dose
Trimetrexate Glucuronate and Protracted 5-Fluorouracil Infusion
in Previously Untreated Patients with Advanced Pancreatic Cancer [Abstract]
Gemcitabine
and Oxaliplatin for Patients with Advanced or Metastatic Pancreatic
Cancer: a North Central Cancer Treatment Group (NCCTG) Phase
I Study [Abstract]
Pancreatic
Resection for Locally Advanced Primary and Metastatic Nonpancreatic
Neoplasms [Abstract]
A
Prospective Cohort Study of Cigarette Smoking and Pancreatic
Cancer in Japan [Abstract]
Indium-111-Pentetreotide
Prolongs Survival in Gastroenteropancreatic Malignancies [Abstract]
Preoperative
Chemoradiation in the Management of Adenocarcinoma of the Body
of the Pancreas [Abstract]
Isis
Pharmaceuticals Reports Preliminary Phase II Data On ISIS 2503
Plus Chemotherapy in Pancreatic Cancer In a planned interim analysis of a Phase II trial of the antisense anti-cancer compound ISIS 2503 in combination with gemcitabine, clinical investigators observed six months or longer survival in patients with pancreatic cancer, surpassing the primary endpoint of the study's defined criteria for success. ...full article
BAY
43-9006 Data Presented at 2002 AACR Meeting Onyx Pharmaceuticals, Inc. announced today that data supporting the mechanism of action of BAY 43-9006, a small molecule Raf kinase inhibitor, were presented at the annual American Association for Cancer Research Conference in San Francisco, California. BAY 43-9006 was identified as part of a joint research effort between Bayer Corporation and Onyx and is being codeveloped by the companies. ...full article
Millennium
Researchers Announce Preclinical Findings of its Proteasome Inhibitor
MLN341 Against Several Solid Tumor Types Millennium Pharmaceuticals, Inc. today announced findings of a preclinical trial of its investigational drug, MLN341 (formerly known as LDP- 341 and PS-341), studying its effects with different chemotherapies against a variety of solid tumors in mice. The results, announced at the annual meeting of the American Association for Cancer Research (AACR) in San Francisco, CA, demonstrated that MLN341, when combined with chemotherapy, consistently caused greater decreases in tumor size than either treatment given alone. ...full article
Lorus
presents new data from its immunotherapeutic program at American
Association for Cancer Research Conference Lorus Therapeutics Inc. announced the presentation of data supporting both the mechanism of action and the characterization of its lead immunotherapeutic product Virulizin®. These findings have led to the development of an immunotherapeutic drug development program that has yielded a novel product with anticancer activity. In vitro and in vivo results of these studies were presented this morning at the annual meeting of the American Association for Cancer Research (AACR) in California. ...full article
GlycoGenesys
and Elan Complete Phase IIa Pancreatic Cancer Study GlycoGenesys, Inc. today announced that its joint venture with Elan Corporation, plc. has completed its Phase IIa clinical trial in refractory or relapsed pancreatic adenocarcinoma cancer patients. Results of the completed trial and pre-clinical studies are being prepared for publication. The Company also announced today that the joint venture has initiated a new Phase I human clinical dose escalation trial with GCS-100, formerly called GBC-590. The study builds on the knowledge gained in the Company's previous Phase IIa colorectal and pancreatic human clinical trials. ...full article
FDA
Grants Approval to Market SecreFlo(TM) for Pancreatic Assessment Repligen Corporation announced today that the United States Food and Drug Administration (FDA) has granted approval to market SecreFlo(TM) (synthetic porcine secretin), the first synthetic version of the hormone secretin. SecreFlo(TM) has been approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, or chronic pancreatitis and stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, a pancreatic tumor which may become cancerous. ...full article
Independent
Review of Phase II Study Confirms SuperGen's Orathecin(TM) Is
Active in Pancreatic Cancer Patients Who Failed Prior Treatments SuperGen Inc. announced today
the long-term follow-up and independent review of results from
a previously announced Phase II clinical study of its oral anticancer
compound Orathecin(TM) (rubitecan) has confirmed the drug's activity
in patients with refractory pancreatic cancer who have failed
prior treatments. The data, previously presented at the 2000
Annual Meeting of the American Society of Clinical Oncology (ASCO),
were reviewed by an independent third-party expert radiology
review panel. ...full article
En
Bloc Resection for Locally Advanced Cancer of the Pancreas. Is
it Worthwhile? [Abstract]
Human
Heparanase-1 Gene Expression in Pancreatic Adenocarcinoma [Abstract]
Cryoablation
of Unresectable Pancreatic Cancer [Abstract]
Is
the Therapeutic Index Better with Gemcitabine-based Chemoradiation
than with 5-fluorouracil-based Chemoradiation in Locally Advanced
Pancreatic Cancer? [Abstract]
Blockade
of Vascular Endothelial Growth Factor Receptor and Epidermal
Growth Factor Receptor Signaling for Therapy of Metastatic Human
Pancreatic Cancer [Abstract]
Parathyroid
Hormone-related Protein as a Novel Tumor Marker in Pancreatic
Adenocarcinoma [Abstract]
Human
Macrophage Metalloelastase Worsens the Prognosis of Pancreatic
Cancer [Abstract]
Dual-Phase
Helical CT of Pancreatic Adenocarcinoma: Assessment of Resectability
Before Surgery [Abstract]
Photodynamic
Therapy for Cancer of the Pancreas [Abstract]
|
||
|
For educational
purposes only and not to be relied upon. Please read Pancreatica
Disclaimer |
||
 Home | In The News | Links | Donations FAQ | Clinical Trials Database | Research Resources | About Us |
||
|
|
||
|
www.pancreatica.org |
||
